TY - JOUR T1 - The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases JF - Pharmacological Reviews JO - Pharmacol Rev SP - 345 LP - 382 DO - 10.1124/pr.117.014878 VL - 71 IS - 3 AU - Luca Antonioli AU - Corrado Blandizzi AU - Pál Pacher AU - György Haskó A2 - Page, Clive Y1 - 2019/07/01 UR - http://pharmrev.aspetjournals.org/content/71/3/345.abstract N2 - Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Despite differing etiologies, these diseases share common inflammatory pathways, which lead to damage in primary target organs and frequently to a plethora of systemic effects as well. The purinergic signaling complex comprising extracellular nucleotides and nucleosides and their receptors, the P2 and P1 purinergic receptors, respectively, as well as catabolic enzymes and nucleoside transporters is a major regulatory system in the body. The purinergic signaling complex can regulate the development and course of IMIDs. Here we provide a comprehensive review on the role of purinergic signaling in controlling immunity, inflammation, and organ function in IMIDs. In addition, we discuss the possible therapeutic applications of drugs acting on purinergic pathways, which have been entering clinical development, to manage patients suffering from IMIDs. ER -